Compare Hims and Hers Health Inc (HIMS) vs Macy's Inc (M) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights executive departures and anticipation for Q2 2026 earnings on August 10, 2026.

The investment outlook is cautiously optimistic, supported by a 35% analyst buy rating and a $33.57 consensus price target. Key opportunities include growth in the weight-loss drug segment and international expansion. Risks involve profitability volatility, intense competition, and reliance on telehealth regulatory frameworks. The stock's valuation remains elevated with a P/E of 57.14, demanding strong future earnings growth to justify current levels.

Macy's (M) trades at $23.80, up 0.51% today, with a bullish technical signal and strong recent earnings beats. The stock shows improving fundamentals with a 2.94% net margin and attractive valuation at a P/E of 9.63. Recent news highlights a successful turnaround under the 'Bold New Chapter' strategy, including same-store sales growth and digital innovation initiatives.

Outlook remains positive with analyst consensus target at $24.83, though risks include margin pressure and retail competition. The stock offers value with upside potential from operational improvements, supported by Berkshire Hathaway's recent 3 million share purchase disclosed in Q1 2026 (13F filing May 15, 2026).